Concord Biotech announced that the US Food and Drug Administration (FDA) has successfully concluded its inspection of the company's Valthera Formulation Facility located at Unit II, Valthera, Dholka Taluka, Ahmadabad district, Gujarat. According to the company's regulatory filing, the inspection was completed with one minor procedural observation that is not related to GMP (Good Manufacturing Practice) standards. The company has committed to submitting a comprehensive response to this observation within the stipulated timeline.
Concord Biotech stated that it does not expect this development to have any material impact on current business operations or existing supplies from the Valthera facility. The company emphasized that the procedural observation is minor in nature and does not affect the facility's manufacturing capabilities or compliance with pharmaceutical standards. This assessment provides clarity for the company's ongoing operations and customer supply chains.
Concord Biotech operates as an R&D-driven biopharma company that manufactures Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, along with finished formulations. As reported by the company, it maintains a presence in more than 70 countries worldwide. The company recently reported strong financial performance with consolidated net profit rising 32.84% to ₹58.53 crore and revenue increasing 26.23% to ₹257.49 crore in Q1 FY27 compared to Q1 FY26.
Following the FDA audit completion announcement, Concord Biotech's stock price rose 1.36% to trade at ₹1,481.95 on the BSE during market hours. This positive market reaction reflects investor confidence in the company's ability to maintain regulatory compliance and continue its growth trajectory in the pharmaceutical sector.
